文献速递肿瘤 PET/CT

[18F]AlF-FAP-NUR PET 的临床综合评价:多时间点显像及与[18F]FDG 的头对头比较

Clinical comprehensive evaluation of [18F]AlF-FAP-NUR PET: multi-time-point imaging, head-to-head comparison with [18F]FDG.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-03-08

这项先导研究纳入 35 例实体瘤患者,评估[18F]AlF-FAP-NUR 的药代动力学、辐射剂量,并与[18F]FDG PET/CT 头对头比较病灶检出;另对 28 例组织样本行 FAP 免疫组化。结果显示该示踪剂主要经肾脏排泄,有效辐射剂量约 1.90E-02 mSv/MBq,病灶检出灵敏度 86.7%、特异度 98.3%,阳性预测值 89.7%,高于 FDG 的 42.3%,且 SUV 与 FAP 表达强相关(SUVmax r=0.7729,P<0.001)。

要点

  • [18F]AlF-FAP-NUR 有效辐射剂量约 1.90E-02 mSv/MBq,主要经肾脏排泄。
  • 病灶检出灵敏度 86.7%、特异度 98.3%,阳性预测值 89.7%。
  • FDG 阳性预测值 42.3%;SUVmax 与 FAP 表达 H 评分相关 r=0.7729。

核心结论

  • 作者认为,这项针对多种实体瘤患者的先导研究显示该示踪剂辐射剂量可接受、生物分布良好,在表达 FAP 的肿瘤中有明显摄取,与 FAP 表达强相关,提示其潜在的临床可用性。

研究设计与样本

  • 研究采用多时间点显像方案,10 例患者用于评估药代动力学和估算辐射剂量,辐射剂量计算使用 OLINDA/EXM 2.0 软件。
  • 头对头比较队列纳入 35 例患者,系统收集并分析原发灶和转移灶的 SUV 与靶本比(TBR),并与[18F]FDG PET/CT 比较。
  • 对 28 例患者的组织样本行 FAP 免疫组化(FAP-IHC)获得 H 评分,并与[18F]AlF-FAP-NUR PET 的 SUV 做相关分析。
  • 统计分析采用非参数检验和相关性评估,显著性阈值设为 P<0.05。

主要发现

  • 多时间点显像显示肿瘤 SUVmax 和 TBR 随时间升高,迅速达峰后处于平台期。
  • [18F]AlF-FAP-NUR 主要经肾脏排泄,有效辐射剂量约 1.90E-02 mSv/MBq。
  • 头对头比较中,[18F]AlF-FAP-NUR 对原发灶和转移灶(尤其淋巴结、骨和肺转移)显示良好检出能力。
  • 经病理确认,[18F]AlF-FAP-NUR PET/CT 检出病灶的灵敏度和特异度分别为 86.7% 和 98.3%。
  • 阳性预测值达 89.7%,为[18F]FDG 阳性预测值 42.3% 的两倍以上。

关键数值与推荐

  • [18F]AlF-FAP-NUR 有效辐射剂量约 1.90E-02 mSv/MBq。
  • 病灶检出灵敏度 86.7%、特异度 98.3%、阳性预测值 89.7%;[18F]FDG 阳性预测值 42.3%。
  • SUVmax 与 FAP 表达(H 评分)相关系数 0.7729(P<0.001)。
  • 统计学显著性阈值设为 P<0.05。

临床怎么用

  • 原文结论称该示踪剂与 FAP 表达强相关,进一步表明[18F]AlF-FAP-NUR PET 具有潜在临床可用性。

局限性

  • 原文将本研究表述为先导研究(pilot study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study was designed to investigate the clinical feasibility of [18F]AlF-FAP-NUR, including the pharmacokinetics, radiation dosimetry estimation, and the head-to-head comparison with [18F]FDG. The head-to-head comparison study was designed to investigate the radiotracer uptake of [18F]AlF-FAP-NUR, to detect the primary and metastatic lesions in patients with various solid cancers, and to compare the results with those of [18F]FDG PET/CT. The correlation of FAP-expression (H-scores) and standardized uptake values (SUVs) derived from [18F]AlF-FAP-NUR were also included. METHODS: Ten patients participated in a multi-time-point imaging protocol aimed at assessing pharmacokinetics and estimating radiation dosimetry. Radiation dosimetry calculations were performed using the OLINDA/EXM 2.0 software. For the comparative analysis between [18F]AlF-FAP-NUR and [18F]FDG PET, a cohort of 35 patients was included. SUVs and tumor-to-background ratios (TBRs) for primary and metastatic lesions were systematically collected and analyzed. To evaluate FAP expression in tissue samples, H-scores were obtained from FAP-immunohistochemistry (FAP-IHC) analyses of samples from 28 patients and correlated with the SUVs measured in [18F]AlF-FAP-NUR PET scans. Statistical analyses included non-parametric tests and correlation assessments, with a significance threshold set at P < 0.05. RESULTS: The study of multi-time-point imaging demonstrated that tumor SUVmax and TBRs increased over time, quickly peaking and remaining in a plateau phase [18F]AlF-FAP-NUR was mainly excreted from kidneys. The effective radiation dose of [18F]AlF-FAP-NUR was approximately 1.90E-02 mSv/MBq. In the head-to-head comparative study, [18F]AlF-FAP-NUR exhibited excellent detection capabilities for both primary and metastatic lesions, particularly in lymph node, bone, and lung metastases. The sensitivity and specificity of [18F]AlF-FAP-NUR PET/CT imaging for detecting lesions, as confirmed by pathology, were 86.7% and 98.3%, respectively. The positive predictive value (PPV) reached 89.7%, more than double that of [18F]FDG (PPV for FDG: 42.3%). Correlation analysis of the SUVs of [18F]AlF-FAP-NUR and FAP expression (based on H-score) showed that SUVs were all strongly correlated with FAP expression, with the SUVmax correlation value being as high as 0.7729 (P < 0.001). CONCLUSION: Our pilot study in patients with various solid tumors has demonstrated acceptable radiation dosimetry, favorable biodistribution, and significant [18F]AlF-FAP-NUR uptake in FAP-expressing tumors. The strong correlation with FAP expression further indicates the potential clinical usability of [18F]AlF-FAP-NUR PET.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang Z, Liu S, Liang S, et al. Clinical comprehensive evaluation of [18F]AlF-FAP-NUR PET: multi-time-point imaging, head-to-head comparison with [18F]FDG. Eur J Nucl Med Mol Imaging. 2025. PMID: 40055208. doi:10.1007/s00259-025-07171-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。